Clinical Trial

AK129 Combination Therapy for Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an open, multicenter phase Ib/II clinical study. The goal of this study is to confirm the Phase II recommended dose (RP2D) of AK129 combinations for advanced solid tumors and evaluate the safety and efficacy of AK129 combinations for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), colorectal adenocarcinoma (CRC), and other advanced solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-17.
Status change: Not Yet Recruiting → Recruiting 2025-05-28
Trial Details
NCT Number NCT06943820
Lead Sponsor Akeso
Conditions Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma, Advanced Solid Tumors
Enrollment 230 participants
Start Date 2025-05-21
Primary Completion 2026-12 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2025-06-03